In the surgical specimens from patients from CANOPY-N who had low baseline CD8+ T-cell infiltration, the levels of viable tumor cells were numerically lower among those treated with the combination of canakinumab and pembrolizumab in comparison with those who received canakinumab alone, suggesting the combination may be more active in this subgroup of patients. The gene discussed is CD8A; the disease is neoplasm.